Risk factor
Limited trading liquidity
Profitability factor
Very favourable analyst view
About
Foresee is a Taiwan and US-based biopharmaceutical company focused on two key areas: its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products for specialty markets, and its transformative preclinical and clinical first-in-class New Chemical Entity (NCE) programs targeting rare and severe disease areas with high unmet needs. Its product portfolio includes late and early-stage programs, with its lead product CAMCEVI® used for the treatment of advanced prostate cancer.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E.